JPRN-jRCT1051210190招募中4 期
The effect of dapagliflozin on allograft function following kidney transplantation: A randomized controlled open-label study (ALL-FOR-ONE study)
Mizui Masayuki0 个研究点目标入组 130 人开始时间: 2022年3月9日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 80age old（—）
- 性别
- All
入选标准
- •All of the following criteria are met
- •(1) Patients aged 20 years or older but less than 80 years
- •(2) Patients with an eGFR of 30 mL/min/1.73 m2 or higher during the screening period (data within 3 months prior to enrollment are acceptable)
- •(3) Patients who have undergone kidney transplantation for more than 1 year
- •(4) Patients who have given written consent
排除标准
- •Patients who meet any of the following criteria will be excluded from this study.
- •(1) Patients with a history of organ transplantation other than kidney
- •(2) Patients on SGLT2 inhibitor (if the medication was terminated more than 6 months ago, it is acceptable)
- •(3) Patients who are not expected to survive for more than 2 years after enrollment
- •(4) Patients who have experienced rejection within 3 months
- •(5) Women who plan to become pregnant within 3 years
- •(6) Lactating women, pregnant women or patients who may be pregnant
- •(7) Patients suffering from active infectious disease
- •(8) Patients with a history of hypersensitivity to the components of dapagliflozin products.
- •(9) Patients who are judged inappropriate by the principal investigator or sub-investigator for other reasons.
研究者
相似试验
进行中（未招募）
1 期
This study is designed to test the hypothesis that the treatment-induced reductions in the ambulatory aortic pressure are more pronounced in the group of dapagliflozin than in the group of placebo (benefit/risk and ethical assessment) and its effects on arterial stiffness and urine albumin excretion in patients with type 2 diabetes.A study of the effects of dapagliflozin on ambulatory aortic pressure, arterial stiffness and urine albumin excretion in patients with type 2 diabetes mellitus.MedDRA version: 18.1Level: LLTClassification code 10029505Term: Non-insulin-dependent diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 18.1Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2015-005288-17-GR???????? ???????? ???????S ????????S?S (Hellenic Society of Medical Education)160
进行中（未招募）
不适用
Impact of treatment with Dapagliflozin in type 1 diabetic patientsType 1 diabetesEUCTR2015-002963-40-ESDra Cristina Avendaño Sola
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-PLAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionMedDRA version: 20.0 Level: PT Classification code 10007558 Term: Cardiac failure chronic System Organ Class: 10007541 - Cardiac disordersEUCTR2016-003897-41-DKAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-BGAstraZeneca AB4,500